| Daniel Eugene Brewer, MD | |
|
1924 Alcoa Hwy, U56, Knoxville, TN 37920-1511 | |
| (865) 305-9081 | |
| (865) 305-8769 |
| Full Name | Daniel Eugene Brewer |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 40 Years |
| Location | 1924 Alcoa Hwy, Knoxville, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013975168 | NPI | - | NPPES |
| 080120660 | Other | RAILROAD MEDICARE | |
| Q010011 | Medicaid | TN | |
| 4273525 | Other | TN | BLUE CROSS BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 19418 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Tn Medical Center | Knoxville, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Health System, Inc. | 5294646378 | 526 |
News Archive
In her latest Kaiser Health News consumer column, Michelle Andrews writes: Most people who smoke want to quit, and the 2010 health-care law is supposed to make it easier for them by requiring many insurance plans to cover smoking-cessation treatments with no out-of-pocket cost to members.
As football players are learning, a violent blow to the head has the potential to cause mild to severe traumatic brain injury - physical damage to the brain that can be debilitating, even fatal. The long-term effects run the gamut of human functioning, from trouble communicating to extensive cognitive and behavioral deterioration. To date, there is no effective medical or cognitive treatment for patients with traumatic brain injuries.
Brooding in your apartment on Saturday afternoon? A new smart phone intuits when you're depressed and will nudge you to call or go out with friends. It's the future of therapy at a new Northwestern University Feinberg School of Medicine center where scientists are inventing web-based, mobile and virtual technologies to treat depression and other mood disorders. The phone and similar projects bypass traditional weekly therapy sessions for novel approaches that provide immediate support and access to a much larger population.
Sinapis Pharma, Inc. announces that its first patients were dosed in a Phase I clinical trial study on June 14, 2010. This study, in human volunteers, is designed to evaluate the safety, pharmacokinetics, and absolute bioavailability of an intravenous infusion of methamphetamine. The first cohort, investigating shorter infusion times, went well. Future cohorts will evaluate longer infusion times and higher drug doses.
› Verified 5 days ago
| Entity Name | University Health System, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790738763 PECOS PAC ID: 5294646378 Enrollment ID: O20031111000809 |
News Archive
In her latest Kaiser Health News consumer column, Michelle Andrews writes: Most people who smoke want to quit, and the 2010 health-care law is supposed to make it easier for them by requiring many insurance plans to cover smoking-cessation treatments with no out-of-pocket cost to members.
As football players are learning, a violent blow to the head has the potential to cause mild to severe traumatic brain injury - physical damage to the brain that can be debilitating, even fatal. The long-term effects run the gamut of human functioning, from trouble communicating to extensive cognitive and behavioral deterioration. To date, there is no effective medical or cognitive treatment for patients with traumatic brain injuries.
Brooding in your apartment on Saturday afternoon? A new smart phone intuits when you're depressed and will nudge you to call or go out with friends. It's the future of therapy at a new Northwestern University Feinberg School of Medicine center where scientists are inventing web-based, mobile and virtual technologies to treat depression and other mood disorders. The phone and similar projects bypass traditional weekly therapy sessions for novel approaches that provide immediate support and access to a much larger population.
Sinapis Pharma, Inc. announces that its first patients were dosed in a Phase I clinical trial study on June 14, 2010. This study, in human volunteers, is designed to evaluate the safety, pharmacokinetics, and absolute bioavailability of an intravenous infusion of methamphetamine. The first cohort, investigating shorter infusion times, went well. Future cohorts will evaluate longer infusion times and higher drug doses.
› Verified 5 days ago
| Entity Name | Parkwest Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396739165 PECOS PAC ID: 8527965417 Enrollment ID: O20040429000423 |
News Archive
In her latest Kaiser Health News consumer column, Michelle Andrews writes: Most people who smoke want to quit, and the 2010 health-care law is supposed to make it easier for them by requiring many insurance plans to cover smoking-cessation treatments with no out-of-pocket cost to members.
As football players are learning, a violent blow to the head has the potential to cause mild to severe traumatic brain injury - physical damage to the brain that can be debilitating, even fatal. The long-term effects run the gamut of human functioning, from trouble communicating to extensive cognitive and behavioral deterioration. To date, there is no effective medical or cognitive treatment for patients with traumatic brain injuries.
Brooding in your apartment on Saturday afternoon? A new smart phone intuits when you're depressed and will nudge you to call or go out with friends. It's the future of therapy at a new Northwestern University Feinberg School of Medicine center where scientists are inventing web-based, mobile and virtual technologies to treat depression and other mood disorders. The phone and similar projects bypass traditional weekly therapy sessions for novel approaches that provide immediate support and access to a much larger population.
Sinapis Pharma, Inc. announces that its first patients were dosed in a Phase I clinical trial study on June 14, 2010. This study, in human volunteers, is designed to evaluate the safety, pharmacokinetics, and absolute bioavailability of an intravenous infusion of methamphetamine. The first cohort, investigating shorter infusion times, went well. Future cohorts will evaluate longer infusion times and higher drug doses.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel Eugene Brewer, MD Po Box 440426, Nashville, TN 37244-0426 Ph: (865) 670-6199 | Daniel Eugene Brewer, MD 1924 Alcoa Hwy, U56, Knoxville, TN 37920-1511 Ph: (865) 305-9081 |
News Archive
In her latest Kaiser Health News consumer column, Michelle Andrews writes: Most people who smoke want to quit, and the 2010 health-care law is supposed to make it easier for them by requiring many insurance plans to cover smoking-cessation treatments with no out-of-pocket cost to members.
As football players are learning, a violent blow to the head has the potential to cause mild to severe traumatic brain injury - physical damage to the brain that can be debilitating, even fatal. The long-term effects run the gamut of human functioning, from trouble communicating to extensive cognitive and behavioral deterioration. To date, there is no effective medical or cognitive treatment for patients with traumatic brain injuries.
Brooding in your apartment on Saturday afternoon? A new smart phone intuits when you're depressed and will nudge you to call or go out with friends. It's the future of therapy at a new Northwestern University Feinberg School of Medicine center where scientists are inventing web-based, mobile and virtual technologies to treat depression and other mood disorders. The phone and similar projects bypass traditional weekly therapy sessions for novel approaches that provide immediate support and access to a much larger population.
Sinapis Pharma, Inc. announces that its first patients were dosed in a Phase I clinical trial study on June 14, 2010. This study, in human volunteers, is designed to evaluate the safety, pharmacokinetics, and absolute bioavailability of an intravenous infusion of methamphetamine. The first cohort, investigating shorter infusion times, went well. Future cohorts will evaluate longer infusion times and higher drug doses.
› Verified 5 days ago
Dr. Ryan Douglas Kerr, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1924 Alcoa Hwy, U56, Knoxville, TN 37920 Phone: 865-305-9081 Fax: 865-305-8769 | |
Landy M Morales, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1924 Alcoa Hwy, Box 56, Knoxville, TN 37920 Phone: 865-305-9081 Fax: 865-305-8769 | |
Sahar M Lotfi, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1924 Alcoa Hwy, U56, Knoxville, TN 37920 Phone: 865-305-9081 Fax: 865-305-8769 | |
Dr. Clayton Devereau Humphrey, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1924 Alcoa Hwy # U56, Knoxville, TN 37920 Phone: 865-305-9081 Fax: 865-305-8769 | |
Dr. Christopher Hill, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1924 Alcoa Hwy # U56, Knoxville, TN 37920 Phone: 865-305-9081 Fax: 865-305-8769 | |
Murad Salaita, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1924 Alcoa Hwy, U56, Knoxville, TN 37920 Phone: 865-305-9081 Fax: 865-305-8769 |